Masimo (MASI) to Release Earnings on Tuesday

Key Points

• Masimo (NASDAQ:MASI) is set to announce its Q2 2025 earnings after market close on August 5th, with analysts predicting earnings of $1.23 per share and revenue of $368.65 million.
• In its last earnings report, Masimo exceeded earnings expectations, posting $1.36 EPS and generating $372 million in revenue, although its revenue declined by 24.5% year-over-year.
• Recent analyst reports have seen fluctuations in ratings and price targets, with a consensus rating of "Moderate Buy" and a price target of $191.60 for the stock.

Masimo (NASDAQ:MASI - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Tuesday, August 5th. Analysts expect Masimo to post earnings of $1.23 per share and revenue of $368.65 million for the quarter. Masimo has set its FY 2025 guidance at 5.300-5.600 EPS.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.12. The firm had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The firm's revenue for the quarter was down 24.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 EPS. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Masimo Stock Performance

Masimo stock traded up $0.56 during mid-day trading on Friday, hitting $154.35. 297,323 shares of the company's stock traded hands, compared to its average volume of 597,005. Masimo has a one year low of $101.61 and a one year high of $194.88. The company has a quick ratio of 1.62, a current ratio of 2.17 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average price of $162.81 and a 200 day moving average price of $165.43. The company has a market cap of $8.37 billion, a PE ratio of -16.85 and a beta of 1.19.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MASI. BTIG Research reiterated a "buy" rating on shares of Masimo in a report on Monday, July 14th. Piper Sandler restated an "overweight" rating and issued a $200.00 target price (down previously from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Wells Fargo & Company lowered their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $191.60.

Insider Buying and Selling at Masimo

In other news, COO Bilal Muhsin sold 10,000 shares of the firm's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the completion of the transaction, the chief operating officer owned 24,172 shares in the company, valued at $3,946,804.16. This trade represents a 29.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 9.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Masimo

Several hedge funds have recently bought and sold shares of MASI. Royal Bank of Canada lifted its position in Masimo by 44.5% during the first quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider's stock worth $7,311,000 after acquiring an additional 13,513 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Masimo by 136.5% in the first quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider's stock valued at $1,305,000 after buying an additional 4,700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Masimo by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider's stock valued at $1,894,000 after buying an additional 66 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Masimo in the first quarter valued at approximately $220,000. Finally, Jones Financial Companies Lllp boosted its stake in shares of Masimo by 1,267.1% in the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider's stock valued at $367,000 after buying an additional 2,040 shares during the period. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.